COVID-19封锁期间地舒单抗给药方案依从性研究
本研究回顾新加坡综合医院电子病历和药房索赔数据库,比较COVID-19封锁期与疫情前地舒单抗6个月给药方案的依从率。封锁期平均依从率为63.9%,疫情前为75.4%;封锁期依从几率显著降低(OR 0.525),内分泌科医生管理的患者依从几率更高(OR 2.516)。
要点
- 封锁期地舒单抗依从率63.9%,显著低于疫情前的75.4%(OR 0.525)。
- 内分泌科管理的患者依从几率高于其他专科(封锁期OR 2.516)。
- 需进一步探索不同专科在用药依从性宣教方面的差异。
核心结论
- COVID-19封锁期间地舒单抗依从性显著低于疫情前。
- 内分泌科医生管理的患者依从几率更高。
研究设计与样本
- 回顾性电子病历与药房索赔数据库研究,地点为新加坡综合医院。
- 依从定义为第二剂在首剂后6个月计划时间点允许延迟最多4周内完成,并进行允许延迟8周的敏感性分析。
主要发现
- 封锁期平均依从率为63.9%,疫情前为75.4%。
- 封锁期依从几率显著低于疫情前(OR 0.525,95%CI 0.430-0.640,p<0.001)。
- 封锁期内分泌科管理患者依从几率高于其他专科(OR 2.516,95%CI 1.836-3.448,p<0.001)。
- 总体内分泌科管理患者依从几率高于其他专科(OR 1.765,95%CI 1.444-2.158,p<0.001)。
临床怎么用
- 在公共卫生突发事件期间应关注慢性骨病患者的用药依从性。
- 内分泌科管理可能与更好地舒单抗依从性相关,可探索其宣教模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: COVID-19 lockdowns have impacted management of chronic diseases such as osteoporosis. Adherence to the 6-monthly dosing schedule of denosumab, the parenteral anti-osteoporosis medication most often used in Singapore, was significantly reduced during the lockdown period compared to that during pre-COVID-19 times. Patients managed by endocrinologists were more likely to be adherent. PURPOSE: No study thus far has quantified actual adherence rates to anti-osteoporosis therapy with denosumab during COVID-19 or explored factors associated with it. We aimed to estimate the adherence rates to denosumab in Singaporean men and women during COVID-19 lockdown and to compare it with those during the pre-COVID-19 period. METHOD: We conducted this retrospective, electronic medical records, and pharmacy claims database study at Singapore General Hospital, the largest hospital in the country. Patients initiated on subcutaneous denosumab between August 2019 and December 2019 and were thus scheduled to receive the second dose during the COVID-19 first-wave period from February 2020 to June 2020 (lockdown group) were analyzed, as were patients initiated anytime on denosumab between September 2011 and December 2018 (pre-COVID-19 group). Data extracted from the hospital's electronic prescription platform and patients' pharmacy purchase records were matched. Adherence was defined as being punctual (with an allowable delay of up to 4 weeks) with the second dose scheduled 6 months from the 1st dose. A sensitivity analysis with an allowable delay up to 8 weeks was also performed. We compared the adherence rates between the two periods and explored factors associated with adherence. RESULTS: A total of 768 and 1458 patients respectively during the lockdown and pre-COVID-19 periods were analyzed. The mean adherence rate during lockdown was 63.9%. The odds of being adherent during lockdown were higher if patients were managed by endocrinologists as opposed to those by other specialists [OR 2.516 (95% CI: 1.836-3.448); p < 0.001]. Adherence rates during the pre-COVID-19 period was 75.4%. Overall, the odds of being adherent to denosumab was significantly lower during lockdown than that during the pre-COVID-19 period [OR 0.525 (95% CI 0.430-0.640); p < 0.001], and odds of being adherent were higher if patients were managed by endocrinologists than if they were managed by other specialists (OR 1.765 (95% CI: 1.444-2.158; p < 0.001). CONCLUSION: Adherence to denosumab was significantly lower during COVID-19 lockdown than the pre-COVID-19 period. The odds of being adherent were higher in patients managed by endocrinologists. Whether healthcare providers from certain specialties spend more time counselling and educating patients about the importance of adherence to osteoporosis medications needs to be explored further.
引用
- Chandran M, Hao Y, Kwee AK, et al. Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia. Osteoporos Int. 2021. PMID: 34417842. doi:10.1007/s00198-021-06085-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。